ADRMONITOR
Italian social screening platform for pharmacovigilance. It watches a pharmaceutical company's own social channels around the clock, flags possible adverse drug reactions with AI, adds daily human review, and produces a timestamped, certifiable audit trail.
What is ADRMONITOR?
ADRMONITOR is a social screening platform published by UpValue srl, a Milan-based pharmaceutical marketing agency. It exists to answer one narrow regulatory obligation: the European Medicines Agency's Good Pharmacovigilance Practices, transposed into Italian law, require marketing authorisation holders to screen at regular intervals the social media and digital environments under their own control, looking for possible reports of adverse drug reactions. UpValue presents ADRMONITOR as the first certified Italian platform supporting pharmaceutical companies in that continuous monitoring, with compliance and full traceability as the promise. The product is not new. It first appeared in February 2018 under the name Adverse Drug Reaction Monitor, described then as a checking platform built on proprietary technology, and was relaunched under the ADRMONITOR name in September 2025. The operating model deliberately mixes machine and human work. Automated monitoring runs around the clock, scanning every thirty minutes. AI algorithms analyse the collected posts and comments, flag candidate adverse reaction cases with a confidence level, and send targeted notifications to the pharmacovigilance team. Qualified operators then perform a manual review twice a day, and weekly and monthly reconciliations are run to guarantee completeness. Five networks are covered, each at a specific granularity: Facebook posts, comments, Messenger, adverts and stories; Instagram posts, comments and stories; X tweets, replies and mentions; YouTube video comments; LinkedIn posts, articles and comments. Content is reached only through the platforms' official APIs. What the customer actually receives is evidence as much as detection. Every activity is logged with a timestamp, an author, an assessment and a status, producing what the vendor calls a complete and certifiable audit trail; screening is recorded even when there is nothing to report, which is precisely what proves the control took place. Certifiable log files and monthly PEC certified emails complete the package, alongside internal SOP and CAPA procedures and audits the vendor says were passed with official certificates. Claimed results include 98% accuracy on identified reports, validation within 12 to 24 hours, over one million logs downloaded and 30,000 messages analysed - all figures published by the vendor, none independently verified.
What it does
- Scan the company's social channels every 30 minutes, 24 hours a day
- Flag possible adverse drug reaction reports using AI, with a confidence level attached
- Submit every flag to a twice-daily manual review by qualified operators
- Alert the pharmacovigilance team with targeted notifications
- Record every action with timestamp, author, assessment and status to build an audit trail
- Reconcile findings weekly and monthly to prove nothing was missed
- Archive captured content so a post deleted by the network does not disappear from the record
When to use ADRMONITOR / When not to
A quick filter to help you decide if ADRMONITOR is the right fit.
When to use ADRMONITOR
- Marketing authorisation holders that must demonstrate regular screening of the social channels under their control
- Pharmacovigilance teams inside pharmaceutical companies who need adverse event signals surfaced daily rather than weekly
- Quality and regulatory managers whose deliverable is evidence: logs, timestamps and audit-ready records
- Pharma marketing and communications teams that run branded social pages and inherit a safety obligation with them
- Companies that would rather outsource the operational burden of continuous social monitoring than staff it internally
When not to use ADRMONITOR
- Anyone wanting to listen to the whole web: the platform covers the company's own social channels, not third-party forums or open social listening
- Buyers who need a published price, a self-service sign-up or a free tier before talking to a salesperson
- Technical teams looking for an API, a mobile app or integration specifications, none of which the vendor publishes
- Organisations working outside Italian and European pharmacovigilance rules, which are the only framework the vendor addresses
- Teams that need documentation and an interface in a language other than Italian, since none is documented
How to use ADRMONITOR
A typical end-to-end flow, from setup to results.
- Establish whether you are a marketing authorisation holder subject to social media screening obligations, since that is the entire premise of the product
- Read the September 2025 article on the UpValue site, which is the only public description of what the platform does
- Get in touch: there is no sign-up, no trial and no public price, so a sales conversation is the only entry point
- Use the enquiry form at the foot of the product article, the contact page, the switchboard on +39 02 25714370, or the CEO's LinkedIn profile linked from the contact page
- Ask for a demonstration of the pharmacovigilance service, which the vendor has offered on request since 2018
- Agree a scope: which brands, which social channels, which networks and which levels of granularity are to be covered
- Grant the platform access to the company's social accounts through the networks' official APIs
- Let automated scanning run every thirty minutes while UpValue's qualified operators perform the twice-daily manual review
- Handle the targeted notifications your pharmacovigilance team receives when a possible adverse reaction is flagged
- Collect the recurring deliverables - dashboard, certifiable log files, monthly PEC certified emails and updated reports - and file them as regulatory evidence
Pros & Cons
Pros
- Answers a precise legal obligation rather than a vague need, which makes the business case easy to state internally
- The audit trail is the product: activity is recorded even when nothing is found, which is exactly what a regulator asks to see
- AI screening is backed by twice-daily human review and periodic reconciliation, not left to run unsupervised
- Content is accessed only through the networks' official APIs, avoiding the legal exposure that scraping creates
- Monthly PEC certified emails give the evidence a form that carries legal weight in Italy
- Archiving protects the record when a post or comment is later deleted from the social network
- Not a recent experiment: the platform dates from 2018 and its publisher has specialised in healthcare communication for years
Cons
- No public price, no tier, no range: every enquiry goes through a sales conversation
- No dedicated product page - the entire public documentation is one blog article and a tile in a catalogue grid
- No API, no mobile app, no technical documentation and no published integration path into an existing pharmacovigilance system
- The claimed certification is never named: no standard, no certifying body, no certificate number, despite the wording first certified Italian platform
- Performance figures - 98% accuracy, 12 to 24 hour validation, one million logs, 30,000 messages - come with no method, no period and no third-party verification
- The published privacy notice covers the website only, so hosting, retention and data ownership for the product itself are undocumented, and it still cites the invalidated EU-US Privacy Shield
- The site contradicts itself: two different phone numbers, and the same catalogue tile points to the 2018 article from the homepage but to the 2025 one from the platforms page
Pricing & Plans
No price is published. ADRMONITOR carries no public rate, no currency, no tier and no indicative range anywhere on the UpValue website, and the site has no pricing page at all. Neither a free plan nor a free trial is announced. Access is by commercial enquiry only: the product article closes by inviting the reader to make contact in order to find out how ADRMONITOR could strengthen their pharmacovigilance system. Prospective buyers should therefore expect a quotation based on scope - brands, channels and networks covered - rather than a published list price.
Data, GDPR & hosting
A consolidated view of how ADRMONITOR handles your data.
GDPR overview
GDPR is claimed explicitly for the product: the vendor lists compliance with European personal data protection guidelines among ADRMONITOR's compliance features and promises maximum GDPR conformity. The publisher is established in Milan, so no Article 27 representative is required or named. The website privacy notice, drafted under Article 13 of Regulation (EU) 2016/679, sets out the usual rights - access, rectification, erasure, restriction, portability, objection, and complaint to the Garante - and names privacy@upvalue.it as the contact. Two caveats matter. That notice governs the website, not the platform: no product-level DPA, hosting location or retention period is published, and the subprocessor list is only available on request. It also still invokes the EU-US Privacy Shield, invalidated in 2020, and carries no effective date.
Who owns the data?
Nothing is published about who owns the data processed by ADRMONITOR itself. The only privacy notice on the site covers the website upvalue.it, where Upvalue srl (VAT 04587830961, Via Teocrito 54, Milan) is named as data controller. For the product, the vendor states that content is reached exclusively through the social networks' official APIs, and that its data storage protects the pharmaceutical company against posts or comments later deleted by the network. That framing suggests the client company is the beneficiary of the archive, but no contractual clause on ownership, reuse or return of product data is available publicly. Treat this as undocumented rather than settled.
Reuse rights
For the product itself, the vendor describes what it does with the material rather than what a customer may do with it: collected social content is analysed by AI algorithms, possible adverse reaction cases are flagged with a confidence level, targeted notifications go to the pharmacovigilance team, and validated cases are archived to feed continuously updated reports. Every action is recorded even when nothing is reported. Whether the client can freely export, reuse or republish that archive is not stated anywhere, and no terms and conditions exist on the site to answer it. On the website side, the privacy notice is explicit but narrow: navigation data serves anonymous statistics only, form data is used solely to answer the enquiry, and CVs only to assess a candidate.
Data retention & training
Hosting summary
No hosting country or region is declared for ADRMONITOR. The vendor publishes nothing about where the platform stores the social content it captures, the validated cases it archives or the logs it produces, and there is no trust or security page on the site. The only jurisdictional statement available comes from the website privacy notice, which concerns upvalue.it rather than the product: data is in principle not transferred outside the European Union, though a transfer to the United States remains possible under the standard contractual clauses adopted by Google, whose Analytics service the site uses. Named recipients on that side are Google and Infarma srl, a company that shares UpValue's registered office; hosting providers are referred to but not named, and the full list of processors is available only on request. The publisher itself is established in Milan, Italy. Note that the website's server resolves to an Italian IP address, but that is a network observation, not a statement about where product data lives.
Things to keep in mind
Risks and trade-offs to weigh before adopting ADRMONITOR.
- The claimed certification is never named - no standard, no notified body, no certificate number - so first certified Italian platform cannot be checked by a buyer
- Every performance figure comes from the vendor: 98% accuracy, 12 to 24 hour validation, one million logs and 30,000 messages carry no method, no period and no external audit
- A screening tool can breed false comfort: a confidence score is not a regulatory decision, and the obligation to assess and report still rests with the company's own pharmacovigilance function
- Nothing is published about where product data is hosted, how long it is kept, or who owns the archive - all of it has to be settled contractually before signing
- The privacy notice still relies on the EU-US Privacy Shield, invalidated in 2020, and carries no effective date, which suggests it has not been reviewed recently
- Monitoring social channels means processing health-related remarks written by identifiable patients, a special category of data under Article 9 that deserves careful handling
- The site contradicts itself on basic facts - two phone numbers, and one catalogue tile pointing to two different articles - so verify anything that matters directly with the vendor
Setup & Integrations
Technical difficulty
Low for the customer, because almost nothing is self-service. No installation procedure is published, and the only technical step implied is granting the platform access to the company's social accounts through the networks' official APIs - an authorisation task rather than an engineering one. Daily operation sits with UpValue's qualified operators, so the client carries little recurring workload. The real effort is contractual and organisational: agreeing scope, and deciding how alerts feed the existing pharmacovigilance process, since no integration into a safety database is documented.
Deployment
Integrations
Behind ADRMONITOR
Social
Resources
All the official URLs gathered for verification and reference.
Frequently asked questions
What is ADRMONITOR for?
Who is it aimed at?
Which social networks are covered?
How is the content collected?
Is there any human control, or is it purely automated?
What happens when there is nothing to report?
What evidence does the platform produce?
How much does it cost?
Is there an API or a mobile app?
Who publishes ADRMONITOR?
Should you pick ADRMONITOR?
ADRMONITOR is a narrow tool for a narrow problem, and that is its strength. It does not try to be a social listening suite; it exists so a marketing authorisation holder can show a regulator that the social channels it controls were screened, continuously, by someone competent. The design follows from that: what the customer really buys is the record - the timestamped audit trail, the certifiable logs, the monthly PEC - as much as the detection itself. Logging screening activity even when nothing is found is the clearest sign that the vendor understood the assignment. Pairing AI flagging with a twice-daily human review and periodic reconciliation is the right shape for a regulated use, where a missed signal and a false alarm carry very different costs. The reservation is commercial opacity. There is no price, no tier, no dedicated product page, no technical documentation and no named certification behind the claim of being the first certified Italian platform. The published performance figures are the vendor's own and come with no method or period. The privacy notice on the site governs the website rather than the platform, so hosting, retention and data ownership for the product remain undocumented, and that notice still leans on an agreement invalidated in 2020. None of this makes the product weak; it makes it impossible to evaluate at a distance. ADRMONITOR suits a pharmaceutical company operating in Italy that is willing to enter a service relationship on quotation, and that will use a first conversation to obtain in writing what the website does not say. The publisher is a long-established Milan agency and the platform itself dates back to 2018, so there is a track record to ask about.
- Choosing a selection results in a full page refresh.
- Opens in a new window.